Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment
Chun Jen Liu(National Taiwan University Hospital), Pei‐Jer Chen(National Taiwan University), Grégory Camus(Gilead Sciences (United States)), Benedetta Massetto(Gilead Sciences (United States)), Vithika Suri(Gilead Sciences (United States)), Rong‐Nan Chien(Chang Gung Memorial Hospital), Tsung‐Hui Hu(National Sun Yat-sen University), Fangqiu Zhang(Gilead Sciences (United States)), Deyuan Jiang(Gilead Sciences (United States)), Cheng‐Yuan Peng(China Medical University), Yu Chun Hsu(Changhua Christian Hospital), Gin Ho Lo(E-Da Hospital), Jenny C. Yang(Gilead Sciences (United States)), Chi Jen Chu(Taipei Veterans General Hospital), Jyh Jou Chen(Chi Mei Medical Center), Horng Yuan Wang(Mackay Memorial Hospital), Kuo Chih Tseng(Taipei Tzu Chi Hospital), Ting Tsung Chang(National Cheng Kung University Hospital), I‐Shyan Sheen(Chang Gung University), Wan‐Long Chuang(Kaohsiung Medical University), Chi Yi Chen(Chia-Yi Christian Hospital), Anuj Gaggar(Gilead Sciences (United States))
Cited by 11
Related Papers
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
|The Lancet. Gastroenterology & hepatology|2016|2k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k